Solventum Corp.
Solventum Corporation (SOLV)
Overview
Solventum is a healthcare technology company spun off from 3M on April 1, 2024, after 3M announced in 2022 that it would separate its healthcare division — roughly a quarter of 3M's sales at the time — into an independent public company. Solventum is headquartered in Maplewood, Minnesota, and sits in the S&P 500's healthcare/medical device and technology sector, with businesses spanning medical-surgical products, dental materials and equipment, and health information technology. The company reported full-year 2025 net sales of about $8.3 billion and had roughly 22,000 employees at the time of its spinoff, making it one of the newest and larger pure-play companies in medtech.
What They Do & How They Make Money
Solventum makes money selling a broad range of products and software to hospitals, surgery centers, dental practices, and healthcare payers/providers, monetizing decades of material-science and health-data expertise inherited from 3M. In its largest business, MedSurg, it sells advanced wound care products (including its market-leading V.A.C. negative-pressure wound therapy systems) and infection prevention and surgical solutions (surgical drapes, sterilization products, skin antiseptics, and related supplies) — recurring, consumable-driven revenue tied to surgical volumes and chronic wound treatment. In Dental Solutions, it sells restorative materials, orthodontic products (brackets, clear aligners technology), and other dental consumables and equipment to dental practices and dental service organizations, monetized through both premium branded consumables and capital equipment sales. Its Health Information Systems (HIS) business is fundamentally different in economics — a software and services business that sells computer-assisted physician documentation, medical coding automation, and revenue-cycle management tools to hospital systems on a SaaS-like, subscription/services model, generating notably higher margins than the company's physical-product segments. Across all three businesses, Solventum benefits from being deeply embedded in customer workflows (operating rooms, dental chairs, hospital billing and coding systems), which creates high switching costs and recurring revenue once its products or software are adopted.
Business Segments
Following the September 2025 divestiture of its Purification and Filtration business (sold to Thermo Fisher Scientific for $4.1 billion), Solventum now operates three ongoing reporting segments:
- MedSurg — The largest segment, combining Advanced Wound Care (FY2025 net sales of about $1.88 billion) and Infection Prevention and Surgical Solutions (about $2.93 billion), for total FY2025 segment net sales of roughly $4.82 billion and operating income of about $810 million (16.8% margin). Includes the V.A.C. wound therapy franchise, where Solventum holds the #1 market position.
- Dental Solutions — Restorative materials (e.g., Filtek), orthodontic products (e.g., Clarity), and other dental consumables and equipment. FY2025 net sales of about $1.35 billion and operating income of about $346 million (25.6% margin).
- Health Information Systems (HIS) — Clinical documentation, autonomous medical coding, and revenue-cycle management software/services for hospital systems, including its 360 Encompass platform. FY2025 net sales of about $1.36 billion and operating income of about $496 million (36.5% margin) — the company's highest-margin segment. In late 2025/early 2026, Solventum announced plans to separate HIS from the rest of the company (via spinoff or sale), citing its distinct, software-like economics and the view that a pure-play HIS company and a pure-play MedTech company would each command a higher valuation than the combined entity.
- Purification and Filtration (divested) — Biopharmaceutical and industrial filtration products; contributed about $497 million of net sales and $96 million of operating income before being sold to Thermo Fisher Scientific in September 2025.
Competitors
- MedSurg / Advanced Wound Care and Surgical Solutions: Medtronic, Smith & Nephew, and 3M (Solventum's former parent, which retains some overlapping surgical and medical-adhesive product lines through licensing/legacy arrangements), along with other surgical supply makers.
- Dental Solutions: Dentsply Sirona and Envista Holdings, the two largest publicly traded dental products competitors, along with Align Technology in orthodontics/clear aligners and other specialty dental material makers.
- Health Information Systems: Oracle Health (formerly Cerner), Nuance/Microsoft, Optum, and a growing set of AI-driven clinical documentation and medical-coding startups.
Competitive Position
Solventum's competitive position varies meaningfully by segment. In MedSurg, it holds the number one position in advanced wound care anchored by its long-established V.A.C. therapy franchise, and it continues to innovate with next-generation systems that add integrated telehealth monitoring — though it faces pricing pressure in general surgical supplies from larger, better-capitalized rivals like Medtronic. In Dental Solutions, Solventum competes on premium brand positioning and material-science innovation (e.g., faster-curing restoratives, advanced orthodontic materials) against Dentsply Sirona and Envista, both of which have significant scale and R&D budgets of their own. Health Information Systems is Solventum's standout franchise: deep integration into hospital clinical and billing workflows creates substantial switching costs and competitive insulation, and its AI-enabled autonomous coding tools directly address hospitals' labor-cost pressures — though this segment also faces the fastest-moving competitive and regulatory environment, given rapid entry by AI-native startups and large platform players like Oracle Health. A key strategic risk and opportunity at once is Solventum's announced plan to separate HIS from its MedTech businesses; management believes this will let each resulting entity be valued as a focused pure-play, but the separation (a spinoff, sale to private equity, or strategic buyer) carries execution risk and could take 12–18 months to complete, and it follows closely on the heels of Solventum's own 2024 separation from 3M — raising questions among some observers about how much more restructuring the company can absorb. More broadly, as a company overall smaller than diversified giants like Medtronic or 3M, Solventum still manages to post strong net margins (around 18% in recent periods), reflecting an efficient, cash-generative operating model, but it must continue investing in R&D and defend share against larger, more diversified competitors across each of its markets.